Skip to content

Multi-omics insights in patient with high-risk, locally advanced, and oligometastatic prostate cancer receiving androgen deprivation therapy

Multi-omics insights in patient with high-risk, locally advanced, and oligometastatic prostate cancer receiving androgen deprivation therapy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300068615
Enrollment
Unknown
Registered
2023-02-24
Start date
2023-02-24
Completion date
Unknown
Last updated
2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Interventions

Experimental Group:none

Sponsors

Xiangya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria. - Age >= 18 years - Willing to provide written informed consent - Histologically confirmed prostate adenocarcinoma (limited high-risk (>= cT3a, or GG >= 4, or PSA > 20ng/ml), locally progressive (any T, N1, M0) and oligometastatic (any T, any N, M1b <= 4 mid-shaft bone metastases)) - Received neoadjuvant therapy based on ADT±ARSI for 3-18 months - Radical prostatectomy (RP) has been performed after neoadjuvant therapy at Xiangya Hospital of Central South University

Exclusion criteria

Exclusion criteria: Exclusion criteria. - Prior radiation therapy, biological therapy - Prior immunotherapy/vaccine therapy for prostate cancer - Prior use of experimental drugs for prostate cancer - Combination therapy with other hormonal therapies or 5 alpha-reductase inhibitors - History or presence of autoimmune disease requiring systemic immunosuppression (including but not limited to: inflammatory bowel disease, systemic lupus erythematosus, vasculitis, rheumatoid arthritis, scleroderma, multiple sclerosis, hemolytic anemia, desiccation syndrome, and nodular disease) - History of malignancy within the past 3 years, except non-melanoma skin cancer and superficial bladder cancer - Uncontrolled major active infectious disease, cardiovascular disease, pulmonary disease, hematologic disease, or psychiatric disease that would make the patient a poor candidate for study - Known past or current history of HIV

Design outcomes

Primary

MeasureTime frame
Pathologic Complete Response;

Secondary

MeasureTime frame
Prostate specific antigen, PSA;clinical stage;MRD;times for neoadjuvant therapy;

Countries

China

Contacts

Public ContactYi Cai

Xiangya Hospital of Central South University, No. 87 Xiangya Road, Kaifu District, Changsha, Hunan Province

cai-yi@csu.edu.cn13637310713

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026